Status:
COMPLETED
CKD-506 Drug-Drug Interaction Study in Healthy Male Subjects
Lead Sponsor:
Chong Kun Dang Pharmaceutical
Conditions:
Drug Drug Interaction
Eligibility:
MALE
20-49 years
Phase:
PHASE1
Brief Summary
This will be a Phase 1, open-label, 1-sequence crossover drug-drug-interaction study in 16 healthy male subjects to assess the effect of single and multiple doses of CKD-506 on the single-dose PK of o...
Eligibility Criteria
Inclusion
- Healthy male subjects
- Ability and willingness to abstain from methylxanthine-containing beverages or food (coffee, tea, cola, chocolate, energy drinks)
- Ability and willingness to abstain from foods and beverages containing grapefruit, Seville oranges, pomelos, star fruit, or cranberries
Exclusion
- History of relevant drug and/or food allergies.
- Using tobacco products
- Positive drug and alcohol screen
Key Trial Info
Start Date :
February 28 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 29 2022
Estimated Enrollment :
17 Patients enrolled
Trial Details
Trial ID
NCT05238948
Start Date
February 28 2022
End Date
April 29 2022
Last Update
August 25 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
PRA Health Sciences
Groningen, Netherlands, 9728